Posted by Michael Wonder on 19 Nov 2022
Iovance Biotherapeutics provides update on biologics license application submission for lifileucel in advanced melanoma
18 November 2022 - BLA submission on-going with US FDA.
Iovance Biotherapeutics today announced that its ongoing rolling biologics license application submission to the US FDA for lifileucel is expected to be completed in the first quarter of 2023.
